[Skip to Content]
[Skip to Content Landing]
November 4, 1988

Low-Molecular-Weight Heparin for Deep Venous Thrombosis-Reply

Author Affiliations

Hôpital Broussais Paris

Hôpital Broussais Paris

JAMA. 1988;260(17):2507-2508. doi:10.1001/jama.1988.03410170055023

In Reply.—  We thank Faivre et al for their interesting comments. The route of administration of heparin therapy is still a matter of debate: Hull et al1 found that the subcutaneous route was less efficient than the intravenous route.The aim of our study was to test the possibility of using LMWH in long-term treatment (and not in the acute phase). We have demonstrated that this treatment is safe and practical: it can be selfinjected and it yields stable biologic activities.The mean phlebographic score from individual score values obtained in our ten patients after a standard initial regimen with intravenous heparin was in good accordance with previously published data.2 The goal of the anticoagulant treatment after the acute phase of DVT is not to achieve significant thrombolysis but to prevent recurrences of DVT and pulmonary embolism. This result was obtained in nine of our ten patients treated